Prothena Reports Q2 2025 Financial Results and Pipeline Progress

Prothena Corporation ( (PRTA) ) has released its Q2 earnings. Here is a breakdown of the information Prothena Corporation presented to its investors.

Prothena Corporation plc is a biotechnology company specializing in the development of therapeutics for neurodegenerative and rare peripheral amyloid diseases, leveraging its expertise in protein dysregulation. In its latest earnings report, Prothena highlighted significant advancements in its pipeline, including the progression of prasinezumab into Phase 3 trials for Parkinson’s disease and the upcoming release of initial data from the Phase 1 ASCENT clinical trials for Alzheimer’s treatment PRX012. Financially, Prothena reported a net loss of $125.8 million for the second quarter of 2025, attributed to restructuring charges and a non-cash income tax expense, with total revenue significantly lower than the previous year due to reduced collaboration revenue. The company maintains a strong cash position of $372.3 million, with expectations to end the year with approximately $298 million. Looking ahead, Prothena plans to convene an Extraordinary General Meeting by year-end to propose a share capital reduction, potentially enabling a share redemption program, while continuing to advance its clinical programs and collaborations.